CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-1135
Issued: 2026-09-04

PRODUCT IDENTIFICATION

PRODUCT Tirzepatide 60 mg	SKU / INTERNAL CODE CRF-2026-1135	PRESENTATION Lyophilised powder, 60 mg vial
BATCH NUMBER LOT-2609-135	CLIENT veltispeptides.mx	SAMPLE RECEIVED 2026-08-28
PRODUCTION DATE 2026-08-25	ANALYSIS DATE 2026-09-02	EXPIRY / RETEST 2028-09-04
MOLECULAR FORMULA C225H348N48O68	MOLECULAR WEIGHT 4813.53	CAS NUMBER 2023788-19-2

ANALYTICAL METHOD

HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS
Instrument: Waters Xevo G3 | Column: C4 2.1×100 mm | Temperature: 60°C
Mobile phase: 0.1% TFA H2O / ACN | Flow: 0.3 mL/min | Injection: 5 µL
Concentration: 0.5 mg/mL | Retention time: 13.6 min

ANALYTICAL RESULTS

Test	Specification	Result	Status
HPLC Purity	≥98.0%	99.3%	PASS
Identity (LC-MS)	4814.5 ±2%	Obs: 4814.9 [M+H]+	PASS
Quantity	95.0–105.0%	59.8 mg (99.7%)	PASS
Endotoxin	<1.0 EU/mg	<0.25 EU/mg	PASS
Heavy Metals	<10 ppm	All <LOQ	PASS

FINAL BATCH RESULT — PASS - Conforms to specifications

ANALYST NOTES

Dual GIP/GLP-1 receptor agonist. High-dose presentation, purity within limits. C20 fatty acid acylation confirmed intact.

crafa

CRAFA

RESEARCH USE ONLY – NOT FOR HUMAN OR VETERINARY USE
Applies only to batch LOT-2609-135. Certificate CRF-2026-1135.
Verify: VEL-1a2b3c4d5e6f7a8b · crafalab.com/verify